PAH
The page defines pulmonary arterial hypertension (PAH) as a rare, progressive, and often fatal condition with high blood pressure in lung vessels.

Gossamer Bio is a clinical-stage biopharmaceutical company developing the investigational drug seralutinib for pulmonary arterial hypertension and interstitial lung disease.
gossamerbio.comCrawled Nov 8, 2026
The page defines pulmonary arterial hypertension (PAH) as a rare, progressive, and often fatal condition with high blood pressure in lung vessels.
The page explains that Gossamer Bio’s name symbolizes fragile connections and its mission to improve patient lives through partnerships and research.
The page describes pulmonary hypertension associated with interstitial lung disease (PH-ILD) as rare, progressive, and often fatal, including PH-IPF and PH related to CTD-ILD.
The page describes seralutinib, an investigational inhaled drug targeting PDGFR, CSF1R, and c-KIT to treat pulmonary hypertension via dry powder inhaler.
Journal Articles
The page warns about job offer scams targeting Gossamer Bio and provides tips to verify legitimate opportunities.
The page describes Mr. Hasnain’s roles as Co-Founder, Chairman, and CEO of Gossamer Bio, and his prior leadership at Receptos and Facet Biotech.
USA Office3115 Merryfield RowSuite 120San Diego, CA 92121 Ireland Office77 Sir John Rogerson’s Quay, Block CGrand Canal DocklandsDublin 2, D02 VK60 Sponsorship DisclosureAnnual Grant & Sponsorship Disclosure Global Reports Grant & Sponsorship Disclosure Global Report 2022 (Download)Grant & Sponsorship Disclosure Global Report 2021 (Download)
Science Seralutinib Seralutinib is an inhaled PDGFRα/β, CSF1R, and c‑KIT inhibitor designed to be delivered via dry powder inhaler for the potential treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The page outlines how Gossamer Bio collects, uses, and protects personal information during recruitment activities.
Gossamer Bio submits a New Drug Application (NDA) to the U.S. FDA for **seralutinib**, a potential treatment for **pulmonary arterial hypertension (PAH)**. The application is backed by data from the **Phase 3 PROSERA study**, the **Phase 2 TORREY study**, and additional supportive analyses. The company now awaits regulatory review for potential approval.
Gossamer Bio adds Greg Ciongoli to its Board of Directors, effective September 16, 2026. Ciongoli joins the clinical-stage biopharmaceutical company, which develops seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). He will also serve on the Audit Committee.
Gossamer Bio implements a **1-for-80 reverse stock split** to adjust its Nasdaq-listed shares (ticker: **GOSS**). The clinical-stage biopharmaceutical company develops **seralutinib**, targeting pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. The move follows a regulatory filing with California’s Secretary of State.
Gossamer Bio reports progress on its **Seralutinib** drug candidate for **pulmonary arterial hypertension (PAH)**, with an **NDA submission** now on track for **September 2026**. The timeline follows the review of **Pre-NDA Type B meeting minutes**, indicating regulatory discussions are advancing. The company also provides a financial update for **Q2 2026** as part of its latest earnings release.
Gossamer Bio secures a path toward submitting a New Drug Application (NDA) for **seralutinib** in pulmonary arterial hypertension (PAH) by **September 2026**, following a **Type B pre-NDA meeting** with the FDA and review of meeting minutes. The company also reacquires worldwide rights to the drug, reinforcing its development pipeline. Gossamer Bio aims to advance seralutinib as a potential treatment for PAH, a rare and progressive cardiovascular disease.